Drug

Tacabrutideg clinical trials

Also written BGB-16673.

studies test it: 10
open now: 9
in phase 3: 2
first study started: 2021

Keep track of what changes. Save the tacabrutideg studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

9 studies that test it; most in 2025 (5); 1 more planned to start later

Studies that test tacabrutideg, by start year
Year	Studies
2021	1
2022	1
2025	5
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 5
Phase 2: 5
Phase 3: 2

What it is tested for

Each study’s main condition, where its own words name it.

Leukemia, Lymphocytic, Chronic, B-Cell: 5
Lymphoma, Non-Hodgkin: 1
Chronic Urticaria: 1

Who runs them

Industry 7 · Other 3

BeOne Medicines (6) · BeiGene (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1)

Often tested with

Tested in the same studies.

Sonrotoclax (1) · Obinutuzumab (1) · Zanubrutinib (1)

Studies

Open first, then newest update. How each study uses tacabrutideg is read from its arms, and is right about nine times in ten.

Testing it · 10

Given in every arm · 3 — tacabrutideg is usual care beside what is tested

Codes

What other systems call tacabrutideg · ClinicalTrials.gg INT017577

UNII (FDA) PF6GPZ4DYTTACABRUTIDEGOne source FDA
NCI Thesaurus C215275TacabrutidegOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	PF6GPZ4DYT	TACABRUTIDEG	One source FDA
NCI Thesaurus	C215275	Tacabrutideg	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.